Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →
CLEATUS
Get CLEATUS

Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)

Active
RFA-CA-28-004Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Cancer Institute is issuing a limited competition Notice of Funding Opportunity, solicitation RFA-CA-28-004, to support the continuation of two critical biospecimen banking resources. These resources include the National Clinical Trials Network Biobanks, which support the NCTN and the Community Oncology Research Program, and the Early-Phase and Experimental Clinical Trials Biospecimen Bank, which supports the ETCTN and other early-phase experimental trials. The primary objective is to maintain national infrastructure for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens to enable translational cancer research, biomarker development, and the study of drug response and resistance. Eligible organizations must submit applications by February 12, 2027, to be considered for funding. All submissions will undergo a standard NIH peer-review process, and only meritorious applications will be selected. These banks are essential for linking biospecimens to clinical outcome data from large multi-site trials and supporting the development of novel cancer therapies through pharmacokinetic and pharmacodynamic analyses.

General Info

NCI funding for two biospecimen banking resources to support translational cancer research.

Agency

National Institutes Of Health → National Cancer Institute

NAICS

621991 - Blood and Organ Banks

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyNational Institutes Of Health → National Cancer Institute
ContactsNo contacts available
OfficeUSA
Organization / AgencyNational Institutes Of Health → National Cancer Institute
Office AddressUSA
ContactsNo contact information available

Full Description

Show more
This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding. Through this limited competition Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications to support continuation of two biospecimen banking resources. The National Clinical Trials Network (NCTN) Biospecimen Banks (NCTN Biobanks) support the NCI-funded NCTN and the Community Oncology Research Program (NCORP), and The Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) supports the Experimental Therapeutics Clinical Trials Network (ETCTN) and other NCI-supported early phase and experimental clinical trials. The objective is to maintain these national resources for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens. The goal of these resources is to ensure the availability of biospecimens from participants in NCI-funded clinical trials focused on treatment, prevention, and cancer control studies to enable translational cancer research. The NCTN Biobanks support biomarker development and validation, secondary correlative studies, and broader scientific discovery using biospecimens collected through harmonized protocols and linked to clinical outcome data from large multi-site clinical trials. The EET Biobank supports biospecimen banking for ETCTN and other early-phase and experimental therapeutic clinical trials involving investigational agents. Biospecimens collected through these studies support biomarker assay development, pharmacokinetic and pharmacodynamic analyses, investigation of drug response and resistance mechanisms, patient stratification, and translational research supporting development of novel cancer therapies. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.

Similar Contracts

Same NAICS industry code

NAICS: 621991
New
Federal
Cadaver Medical Training SupportThe Cadaver Medical Training Support subcontract, issued by the Department of Defense under W40M MRC0 West, involves providing technical and logistical assistance to prime contractors for medical training projects. The scope of work focuses on operational support for training days, specifically the preparation and management of cadavers utilizing specialized medical training lab equipment. The contract specifies a delivery requirement of 10 units of support and 10 training days per year. To ensure installation access, personnel are required to complete Anti-Terrorism Level I and iWatch training. This opportunity falls under NAICS code 621991 and is performed in the 78234 zip code area. Interested parties should note the response deadline of October 30, 2026.
W40M MRC0 West

POSTED

1 day ago

DEADLINE

in 13 days
View Details
NAICS: 621991
New
Federal
Human Cadaver - Based Medical Training and Program Support Services for the 44th Medical Brigade stationed at Fort Bragg Army Base, North Carolina.
Solicitation # 0012468284
The Medical Acquisition Support Office – Alpha is conducting a Sources Sought notice to identify capable vendors for Human Cadaver-Based Medical Training and Program Support Services for the 44th Medical Brigade. The requirement involves the procurement and delivery of up to 20 ethically sourced, non-dissected, perfused human cadaver specimens annually, which must be serologically negative for HIV-1/2, Hepatitis B/C, and Syphilis. The contractor must be certified by the American Association of Tissue Banks or an equivalent body and provide refrigerated transportation to primary performance sites including Fort Bragg, NC; Fort Campbell, KY; Fort Stewart-Hunter Army Airfield, GA; and Fort Polk, LA. The scope also includes providing medical equipment, Class VIII supplies, and comprehensive program administration. The anticipated contract structure consists of a base period followed by four one-year option periods. Key deliverables per year include 20 cadavers, 10 additional training days, 10 units of Subject Matter Expert (SME) support, and 10 units of cadaver medical training support. SMEs must be board-certified general surgeons with specific competencies in a wide range of surgical procedures, such as cricothyroidotomy and exploratory laparotomy. Additionally, all contractor personnel must comply with Installation Access Control requirements, including the completion of Anti-Terrorism Level I and iWatch training. This notice is for planning purposes under NAICS 621991 to determine market capacity and formulate an acquisition strategy.
W40M MRC0 West

POSTED

1 day ago

DEADLINE

in 13 days
View Details
NAICS: 621991
New
Federal
6505--Human Blood and Blood Products
Solicitation # 36C25727Q0049
The Department of Veterans Affairs, Network Contracting Office 17, intends to award a single-award, firm-fixed-price Indefinite Delivery/Indefinite Quantity (IDIQ) contract to the South Texas Blood and Tissue Center. This procurement is for the supply and delivery of human blood and blood products, as well as guidance in clinical pathology procedures, to support the Audie L. Murphy Veterans Health Care Center within the South Texas Veterans Health Care System in San Antonio, Texas. The government is pursuing this as a sole source procurement under the authority of 41 U.S.C. 3304(a)(1) and FAR 6.103-1, asserting that only one responsible source can satisfy the agency's requirements. The contractor must maintain AABB and College of American Pathologists (CAP) accreditation and hold an unrevoked U.S. license from the FDA Bureau of Biologics. Key operational requirements include 24/7/365 availability and a tiered delivery system: STAT orders must be delivered within 60 minutes, ASAP orders within 2 hours, and routine orders within 24 hours. All products must be collected via closed systems under aseptic conditions, labeled according to the ABO Blood Group System and Rh type, and transported in compliance with FDA, AABB, and DOT regulations to ensure proper temperature maintenance. Acceptance of deliveries is based on STVHCS Blood Bank criteria, including physical appearance, contamination checks, and specific shelf-life minimums for red blood cells, plasma, and cryoprecipitate.
257-NETWORK Contract Office 17 (36C257)

POSTED

3 days ago

DEADLINE

in 18 days
View Details
NAICS: 621991
New
Grant
Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-004
The National Cancer Institute (NCI) has issued a Limited Competition Notice of Funding Opportunity (RFA-CA-28-004) to support the continuation of two critical biospecimen banking resources: the National Clinical Trials Network (NCTN) Biobanks and the Early-Phase and Experimental Clinical Trials (EET) Biobank. The primary objective is to maintain these national resources for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens. These resources facilitate translational cancer research, biomarker development, and validation by providing essential specimens from NCI-funded clinical trials. The NCI intends to fund approximately six awards for fiscal year 2027, with a total estimated funding of 19 million dollars and a maximum budget of 3 million dollars in direct costs per year for a requested project period of six years. Applications will be evaluated through the NIH peer-review system based on scientific and technical merit, significance, and the adequacy of the institutional environment. Key requirements for applicants include maintaining active registrations in SAM, eRA Commons, and Grants.gov, as well as providing specific documentation regarding the current scale of operations, accomplishments, and standard operating procedures. Awardees must adhere to NCI Best Practices for Biospecimen Resources, federal human subjects regulations under 45 CFR 46, and strict cybersecurity incident reporting protocols, including notification of incidents within 48 hours of discovery. The scope of work includes managing secure informatics systems, providing specimen collection kits, and ensuring the availability of annotated biospecimens for authorized investigators.
National Institutes Of Health

POSTED

3 days ago

DEADLINE

in 4 months
View Details
NAICS: 621991
Federal
Anatomical Supplies in support of Defense Medical Readiness Training Institute
Solicitation # PANDHA26P0000049466
The Defense Health Agency intends to award a sole-source contract to Experience Anatomy, LLC for the procurement of fresh or fresh-frozen cadavers. These anatomical supplies will support the Emergency War Surgery Course hosted by the Defense Medical Readiness Training Institute at Madigan Army Medical Center in Tacoma, Washington, providing critical training in Advanced Surgical Skills for Exposure in Trauma for military physicians and surgeons. While this notice is not a request for competitive proposals, interested parties have until October 20, 2026, to submit capability information demonstrating their ability to meet the requirements. The government maintains sole discretion on whether to compete the contract based on these submissions and will not reimburse costs for providing this information. Proposals, quotations, and marketing materials are explicitly prohibited at this stage.
Defense Health Agency

POSTED

12 days ago

DEADLINE

in 3 days
View Details
NAICS: 621991
SLED
Kidney Transplant Exemption
Solicitation # 2139277
SUNY Downstate Health Sciences University has issued a notice for a single source exemption under solicitation number 2139277 to support its Kidney Transplant Program. This procurement action, which was posted on September 22, 2026, follows the approval of a CRER request by the Office of the State Comptroller on September 18, 2026. The scope of the procurement is specifically tied to the Kidney Transplant Unit having received a kidney for its program. The performance for this action is located at 450 Clarkson Avenue, Brooklyn, New York. As this is a notice of a procurement exempt from advertising, there are no competitive evaluation factors, listed contract terms, or specified contract values. The primary point of contact for this action is Purchase Associate Joanne Fraser.
State University of New York (SUNY)

POSTED

26 days ago

DEADLINE

N/A
View Details
NAICS: 621991
Grant
Somatic Mosaicism across Human Tissues (SMaHT) Program: Tissue Procurement Center (R24 Clinical Trial Not Allowed)The National Institutes of Health is seeking a Tissue Procurement Center to support the Somatic Mosaicism across Human Tissues (SMaHT) Network. The primary goal of this initiative is to advance the understanding of biological processes and disease mechanisms driven by somatic mutations in human tissues. The center will be responsible for the collection, processing, storage, and distribution of high-quality human tissue specimens to enable functional analyses and the characterization of somatic mosaicism. The program aims to expand its existing foundation of 150 healthy donors by procuring tissues from at least 50 additional healthy individuals, reaching a total of 200. Additionally, the center will collect up to 10 special tissue cohorts, which may include clinically relevant samples, tissues suitable for culture, or organs requiring specialized handling. The awardee will collaborate with other SMaHT Stage 2 initiatives to ensure that all samples are sufficient for production-level assays.
National Institutes Of Health

POSTED

about 1 month ago

DEADLINE

N/A
View Details
NAICS: 621991
Federal
Blood SamplesThe Department of Commerce is seeking to procure healthy GMP-grade Leukopaks and fresh healthy whole blood samples. These biological materials will be utilized for forensic DNA testing, the production of standard reference materials, the execution of inter-laboratory studies, and the publication of allele frequencies. This requirement is listed as a forecast with the place of performance located in Gaithersburg. The procurement falls under NAICS code 621991, and interested parties may coordinate with the designated point of contact, Daniel Dender, or the Office of Small and Disadvantaged Business Utilization.

POSTED

about 2 months ago

DEADLINE

N/A
View Details
NAICS: 621991
Federal
Inpatient and Off-Site Facility CoordinationThis subcontract, titled Inpatient and Off-Site Facility Coordination, is issued by the Department of Justice under the agency Fao. The primary scope of work involves the arrangement and monitoring of off-site hospitalizations, diagnostic procedures, and specialty inpatient care, with a specific focus on managing the associated transport logistics. The contract is categorized under NAICS code 621991 and is designated for performance in Pine Knot, Kentucky, 42635. It was posted on August 14, 2026, and is available for further review through the official government workspace link.
Fao

POSTED

2 months ago

DEADLINE

N/A
View Details
NAICS: 621991
SLED
Mobile Health Unit OperationsThe contract titled Mobile Health Unit Operations seeks a subcontractor to manage the operation and maintenance of mobile units tasked with delivering vision, dental, and hearing services to underserved communities across the region. These mobile units will serve as critical access points for essential health care, ensuring that populations with limited transportation or geographic barriers receive timely and consistent medical attention. The work involves the full lifecycle management of the units, including routine maintenance, repairs, staffing coordination, logistics, and compliance with health and safety standards to guarantee reliable service delivery. The contract is categorized as a subcontract under NAICS code 621991 and is solicited by the Houston-Galveston Area Council through the Texas SmartBuy platform. The solicitation was posted on July 22, 2026, with a response deadline of July 29, 2027, providing over a year for prospective vendors to prepare proposals. The place of performance spans the region served by the council, though exact locations are not specified, indicating flexibility in service deployment based on community need. While details on set-aside status and point of contact are unavailable, the focus remains on operational excellence and equitable access to preventive and diagnostic health services in areas lacking permanent clinical infrastructure.
HOUSTON-GALVESTON AREA COUNCIL

POSTED

3 months ago

DEADLINE

in 9 months
View Details
NAICS: 621991
Grant
Continuation and Expansion of the National Mesothelioma Virtual Bank for Translational Research (U24)The National Mesothelioma Virtual Bank, managed by the Centers for Disease Control and Prevention under the Department of Health and Human Services, is a translational research initiative focused on advancing biomedical research for malignant mesothelioma. This forecast opportunity aims to expand the existing virtual registry and tissue bank by integrating additional biospecimens, such as frozen tumor tissues, blood, DNA, and protein samples, with comprehensive demographic and clinical data. By providing a shared repository of genomic, transcriptomic, and proteomic data, the project supports the identification of early disease signs, the development of prognostic biomarkers, and the creation of improved treatment options. The primary objective is to enhance the bank's capacity as a critical resource for the clinical science community and biomedical researchers. This effort is categorized under NAICS code 621991 and is designed to facilitate the sharing of high-quality specimens and data to accelerate breakthroughs in mesothelioma research.
Centers For Disease Control And Prevention

POSTED

3 months ago

DEADLINE

N/A
View Details
NAICS: 621991
Federal
Deceased Donor Organ Recovery ServicesThis contract involves the clinical and logistical coordination necessary for the recovery of deceased donor organs at hospital settings. The scope includes organizing surgical teams and managing donor cases to ensure the efficient and effective retrieval of organs for transplant purposes. The services are designed to support hospital operations and facilitate timely donor organ recovery, which is critical for successful transplantation outcomes. Awarded by the Department of Veterans Affairs under the 244-NETWORK Contract Office 4, the contract is classified under the NAICS code 621991, which pertains to ambulatory health care services. Although specific details such as the place of performance, solicitation number, and point of contact are not provided, the contract clearly targets the provision of specialized clinical support in organ procurement, reinforcing the agency’s commitment to healthcare and transplant services.
244-NETWORK Contract Office 4 (36C244)

POSTED

5 months ago

DEADLINE

N/A
View Details

More opportunities from National Institutes Of Health → National Cancer Institute

Same awarding agency

NAICS: 541714
New
Grant
Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)
Solicitation # PAR-28-014
The National Cancer Institute, under the National Institutes of Health, is soliciting applications for solicitation PAR-28-014 to investigate the causes and biological mechanisms of sporadic non-hereditary early-onset cancers in adults aged 18 to 49. The primary goal of this initiative is to understand the rising incidence of these cancers to improve prevention and control strategies. Research should specifically target environmental or lifestyle drivers across various demographics, the biological host responses involved, or the development of more effective methods for identifying high-risk individuals. This funding opportunity supports both standard research projects and exploratory or developmental studies through a grant award instrument, with clinical trials being optional. Interested parties must submit their applications by the deadline of October 12, 2029.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

4 days ago

DEADLINE

in almost 3 years
View Details
NAICS: 541714
New
Grant
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
Solicitation # PAR-28-022
The National Cancer Institute, potentially in collaboration with the National Institute of Dental and Craniofacial Research, is soliciting applications for P50 Research Center Grants for Specialized Programs of Research Excellence. This program supports investigator-initiated translational research focused on the prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related cancer groups. Eligible research must be grounded in human biology using genetic, molecular, biochemical, structural, or cellular experimental approaches and must achieve a translational human endpoint within the grant period. Under solicitation number PAR-28-022, this opportunity covers the years 2027, 2028, and 2029 and requires the inclusion of clinical trials. The notice was posted on October 14, 2026, with a final response deadline of September 26, 2029. This initiative serves as a re-issuance of PAR-23-284 to continue funding state-of-the-art research aimed at improving clinical outcomes for cancer patients.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

4 days ago

DEADLINE

in almost 3 years
View Details
NAICS: 541715
Grant
Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-013
The National Cancer Institute, under the National Institutes of Health, is seeking meritorious proposals for the Carcinogen Hazard Assessment Monographs Program (CHAMP) Initiative. This solicitation, identified as RFA-CA-28-013, aims to fund projects that critically and systematically evaluate scientific evidence regarding carcinogenic hazards to humans to better inform cancer research, control, and prevention efforts. Interested applicants must submit their proposals by the response deadline of February 10, 2027. This opportunity is categorized as an R01 grant, and it is explicitly noted that clinical trials are not allowed under this specific funding program.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

in 4 months
View Details
NAICS: 541714
Grant
Notice of Change in Application Due Date for RFA-CA-27-005 "Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)"
Solicitation # NOT-CA-26-020
This notice issued by the National Cancer Institute of the National Institutes of Health serves to amend the application timeline for the Glioblastoma Therapeutics Network clinical trial solicitation, RFA-CA-27-005. The primary modification is the addition of a second application due date on January 11, 2027, for new, renewal, resubmission, and revision applications. Under this new cycle, the scientific merit review is scheduled for June 2027, followed by an advisory council review in August 2027, with an earliest start date of December 2027. The expiration date for this specific window is January 12, 2027. All other terms and conditions of the original notice of funding opportunity remain unchanged.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

18 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)
Solicitation # PAR-28-057
The National Cancer Institute is soliciting applications under solicitation PAR-28-057 to establish the Management and Data Coordination Unit as a key scientific component of the Pancreatic Cancer Detection Consortium. This initiative focuses on the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions to identify high-risk patients, aligning with the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The selected unit will be responsible for providing critical infrastructure and collaborative support, including study design, protocol development, statistical analysis, and comprehensive data management. Additionally, the unit will oversee the coordination of biorepository building and provide the necessary organizational and logistics support to ensure the successful operation of the consortium. Applications must be submitted by the deadline of May 26, 2027.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

23 days ago

DEADLINE

in 7 months
View Details
NAICS: 541714
Grant
Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
Solicitation # PAR-28-056
The National Cancer Institute is soliciting applications for Research Units as part of the Pancreatic Cancer Detection Consortium to advance the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions. These multi-disciplinary teams will focus on developing and testing molecular and imaging biomarkers to identify high-risk patients and those with lesions likely to progress to cancer. Key research activities include the use of machine learning for biomarker discovery, conducting validation studies, and collecting longitudinal biospecimens for a centralized biorepository. Under solicitation PAR-28-056, the selected Research Units are required to engage in collaborative efforts, sharing data and biospecimens across the consortium. The initiative aligns with the NCI's scientific framework for pancreatic cancer by prioritizing the identification of patients who could benefit from early intervention based on genetic factors, family history, or existing precursor lesions. Applications for this federal opportunity are due by November 6, 2029.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

23 days ago

DEADLINE

in about 3 years
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS